Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 260


Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort.

Szük T, Gyöngyösi M, Homorodi N, Kristóf E, Király C, Edes IF, Facskó A, Pavo N, Sodeck G, Strehblow C, Farhan S, Maurer G, Glogar D, Domanovits H, Huber K, Edes I.

Am Heart J. 2007 Feb;153(2):289-95.


Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.

Motovska Z, Kala P.

Clin Ther. 2008;30 Pt 2:2191-202. doi: 10.1016/j.clinthera.2008.12.001. Review.


Impact of high loading and maintenance dose of clopidogrel within the first 15 days after percutaneous coronary intervention on patient outcome.

Lemesle G, Delhaye C, Sudre A, Broucqsault D, Rosey G, Bauters C, Lablanche JM.

Am Heart J. 2009 Feb;157(2):375-82. doi: 10.1016/j.ahj.2008.09.013. Epub 2008 Nov 1.


Clopidogrel is associated with better in-hospital and 30-day outcomes than ticlopidine after coronary stenting.

L'Allier PL, Aronow HD, Cura FA, Bhatt DL, Albirini A, Schneider JP, Topol EJ, Ellis SG.

Can J Cardiol. 2003 Aug;19(9):1041-6.


Clopidogrel as adjunctive antiplatelet therapy during coronary stenting.

Mishkel GJ, Aguirre FV, Ligon RW, Rocha-Singh KJ, Lucore CL.

J Am Coll Cardiol. 1999 Dec;34(7):1884-90.


Clopidogrel for prevention of major cardiac events after coronary stent implantation: 30-day and 6-month results in patients with smaller stents.

Calver AL, Blows LJ, Harmer S, Dawkins KD, Gray HH, Morgan JH, Simpson IA.

Am Heart J. 2000 Sep;140(3):483-91.


High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease.

Migliorini A, Valenti R, Marcucci R, Parodi G, Giuliani G, Buonamici P, Cerisano G, Carrabba N, Gensini GF, Abbate R, Antoniucci D.

Circulation. 2009 Dec 1;120(22):2214-21. doi: 10.1161/CIRCULATIONAHA.109.883454. Epub 2009 Nov 16.


A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents.

Mueller C, Roskamm H, Neumann FJ, Hunziker P, Marsch S, Perruchoud A, Buettner HJ.

J Am Coll Cardiol. 2003 Mar 19;41(6):969-73.


Comparison of higher clopidogrel loading and maintenance dose to standard dose on platelet function and outcomes after percutaneous coronary intervention using drug-eluting stents.

Abuzahra M, Pillai M, Caldera A, Hartley WB, Gonzalez R, Bobek J, Dokainish H, Lakkis N.

Am J Cardiol. 2008 Aug 15;102(4):401-3. doi: 10.1016/j.amjcard.2008.03.073. Epub 2008 May 28.


Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.

Cuisset T, Frere C, Quilici J, Morange PE, Nait-Saidi L, Carvajal J, Lehmann A, Lambert M, Bonnet JL, Alessi MC.

J Am Coll Cardiol. 2006 Oct 3;48(7):1339-45. Epub 2006 Sep 12.


Efficacy of high-dose clopidogrel treatment (600 mg) less than two hours before percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes.

Feldman DN, Fakorede F, Minutello RM, Bergman G, Moussa I, Wong SC.

Am J Cardiol. 2010 Feb 1;105(3):323-32. doi: 10.1016/j.amjcard.2009.09.034. Epub 2009 Dec 22.


A high maintenance dose of clopidogrel improves short-term clinical outcomes in patients with acute coronary syndrome undergoing drug-eluting stent implantation.

Han YL, Wang B, Li Y, Xu K, Wang SL, Jing QM, Wang ZL, Wang DM, Ma YY, Wang G.

Chin Med J (Engl). 2009 Apr 5;122(7):793-7.


Clinical relevance of clopidogrel unresponsiveness during elective coronary stenting: experience with the point-of-care platelet function assay-100 C/ADP.

Moerenhout CM, Claeys MJ, Haine S, Miljoen H, Bosmans JM, Vertessen F, Kluppels K, Van der Planken M, Vrints CJ.

Am Heart J. 2010 Mar;159(3):434-8. doi: 10.1016/j.ahj.2009.12.020.


Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.

Ebrahimi R, Dyke C, Mehran R, Manoukian SV, Feit F, Cox DA, Gersh BJ, Ohman EM, White HD, Moses JW, Ware JH, Lincoff AM, Stone GW.

J Am Coll Cardiol. 2009 May 26;53(21):1965-72. doi: 10.1016/j.jacc.2009.03.006.


Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET).

Chan AW, Moliterno DJ, Berger PB, Stone GW, DiBattiste PM, Yakubov SL, Sapp SK, Wolski K, Bhatt DL, Topol EJ; TARGET Investigators.

J Am Coll Cardiol. 2003 Oct 1;42(7):1188-95.


Safety and efficacy evaluation of clopidogrel compared to ticlopidine after stent implantation: an updated meta-analysis.

Casella G, Ottani F, Pavesi PC, Sangiorgio P, Rubboli A, Galvani M, Fontanelli A, Bracchetti D.

Ital Heart J. 2003 Oct;4(10):677-84.


Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention.

Hochholzer W, Trenk D, Frundi D, Blanke P, Fischer B, Andris K, Bestehorn HP, Büttner HJ, Neumann FJ.

Circulation. 2005 May 24;111(20):2560-4. Epub 2005 Apr 4.


Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial.

Gurbel PA, Cummings CC, Bell CR, Alford AB, Meister AF, Serebruany VL; Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial.

Am Heart J. 2003 Feb;145(2):239-47.


Supplemental Content

Support Center